Uneven market recovery and differing customer priorities are pushing CDMOs to rethink how they demonstrate value and deliver on pharma’s expectations, finds Simon-Kucher.
This presentation addresses key considerations for developing and validating ADC-specific analytical methods, including DAR distribution, free payload, conjugational heterogeneity, product-related impurities and functional potency.